SCHEMBL8214784

SCHEMBL8214784

CC(=O)CCc1ccc(CO)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.65
KDM4E B2RXH2 1/20 0.49
NPC1 O15118 1/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
MAPT P10636 1/20 0.49
MAOA P21397 1/20 0.49
SLC6A2 P23975 1/20 0.49
RAB9A P51151 1/20 0.49
SLC6A3 Q01959 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
FFAR1 O14842 5/20 0.43
KEAP1 Q14145 1/20 0.41
F2RL1 P55085 1/20 0.41
HSD17B10 Q99714 1/20 0.41
IAPP P10997 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10912165 0.91 ALDH1A1 (0.77) ALDH1A1KDM4ENPC1LMNATP53
Benzylacetone SCHEMBL6813564 0.90 ALDH1A1 (0.84) ALDH1A1KDM4ENPC1MAPTRAB9A
SCHEMBL1909485 0.87 HSD17B10 (0.52) ALDH1A1NPC1RAB9ASLC6A3SMN1; SMN2
SCHEMBL12354595 0.84 F2RL1 (0.53) ALDH1A1KDM4ECYP4F2CYP4A11FFAR1
SCHEMBL15445002 0.82 CYP1A2 (0.68) ALDH1A1KDM4ENPC1LMNATP53
SCHEMBL11444235 0.82 ALDH1A1 (0.65) ALDH1A1KDM4ENPC1LMNATP53
SCHEMBL5534617 0.82 ALDH1A1 (0.65) ALDH1A1KDM4ENPC1LMNATP53
SCHEMBL363773 0.82 ALDH1A1 (0.65) ALDH1A1KDM4ENPC1LMNATP53
Raspberryketone SCHEMBL43308 0.82 ALDH1A1 (0.65) ALDH1A1KDM4ENPC1LMNATP53
SCHEMBL11443198 0.82 ALDH1A1 (0.65) ALDH1A1KDM4ENPC1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114748516-A Application of Coptis japonica root in preparing medicament for treating osteoarthritis 丽水市中医院 2022-07-15 CN disclosed
CN-114748516-A Application of Coptis japonica root in preparing medicament for treating osteoarthritis 丽水市中医院 2022-07-15 CN disclosed
US-9273003-B2 Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-03-01 US disclosed
US-9273003-B2 Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-03-01 US disclosed
US-20140323531-A1 HDAC INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-10-30 US disclosed
US-20140323531-A1 HDAC INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-10-30 US disclosed
US-20130165446-A1 BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE HORIKOSHI, HIROYOSHI (CA) 2013-06-27 US disclosed
WO-2008047382-A2 A PROCESS FOR THE PREPARATION OF 4-[2-[[3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]AMINO]ETHYL]-1,2-BENZENEDIOL SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323531-A1 HDAC INHIBITORS HDAC1, HDAC3, HDAC2 ALDH1A1 626/4885KDM4E 71/4885NPC1 1434/4885
US-20130165446-A1 BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE PPARG, PPARA, PPARD ALDH1A1 1612/4885KDM4E 1152/4885NPC1 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.